Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Riluzole in Hereditary Cerebellar Ataxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with genetically confirmed diagnosis of hereditary cerebellar ataxia~Exclusion Criteria:~* Concomitant experimental therapy for ataxia~* Serious systemic illnesses~* Pregnancy

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Riluzole (Type: EXPERIMENTAL): Riluzole 50 mg is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
- Placebo comparator (Type: PLACEBO_COMPARATOR): Placebo is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)

Based on this trial design, predict the completion outcome and termination type (if applicable).